NCT00095524已完成3 期
A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.32 个研究点 分布在 3 个国家目标入组 300 人开始时间: 2004年3月最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 32
- 主要终点
- Comparison of weight change from baseline to Week 16 in patients with schizophrenia or schizoaffective disorder treated with aripiprazole or olanzapine
研究概览
简要总结
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients diagnosed with schizophrenia or schizoaffective disorder who are currently taking olanzapine.
排除标准
- 未提供
结局指标
主要结局
Comparison of weight change from baseline to Week 16 in patients with schizophrenia or schizoaffective disorder treated with aripiprazole or olanzapine
次要结局
- Assessment of metabolic laboratory measures
研究者
研究点 (32)
Loading locations...
相似试验
已完成
4 期
Study of Olanzapine vs. Aripiprazole in the Treatment of SchizophreniaSchizophreniaNCT00088049Eli Lilly and Company560
已完成
3 期
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute SchizophreniaSchizophreniaNCT00712686Otsuka Pharmaceutical Development & Commercialization, Inc.690
已完成
3 期
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's TypeDementia, Alzheimer TypeNCT01438060Otsuka Pharmaceutical Development & Commercialization, Inc.232
已完成
4 期
Study of Aripiprazole in Subjects With AlcoholismAlcoholismNCT00082199Otsuka Pharmaceutical Development & Commercialization, Inc.400
已完成
3 期
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I DisorderBipolar Disorder ManiaNCT00665366Otsuka Pharmaceutical Development & Commercialization, Inc.493